# Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

> **NCT06441110** · PHASE3 · RECRUITING · sponsor: **Fujian Medical University Union Hospital** · enrollment: 76 (estimated)

## Conditions studied

- Urinary Bladder Neoplasms
- BCG Vaccine
- Immunotherapy, Active
- Multicenter Study
- Treatment Outcome
- Neoplasm Recurrence, Local

## Interventions

- **DRUG:** Tislelizumab in Combination with Bacillus Calmette-Guérin

## Key facts

- **NCT ID:** NCT06441110
- **Lead sponsor:** Fujian Medical University Union Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2035-06-01
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2024-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06441110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06441110, "Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06441110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*